GH — Guardant Health Inc
NASDAQ · Health Care · Health Care
- Latest Close
- $90.36
- 30-Day Move
- -10.9%
- Market Cap
- $12.3B
- Shares Outstanding
- 131,170,000
- P/B Ratio
- 20.69
- ROE
- -302.1%
Analyst consensus: Buy · 34 analysts
Guardant Health Inc
A read-only Alphactor snapshot forGuardant Health Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$90.36
30-Day Move
-10.9%
Market Cap
$12.3B
Shares Outstanding
131,170,000
P/B Ratio
20.69
ROE
-302.1%
$90.36
-10.9%last 90 delayed daily bars
90D High
$120.74
90D Low
$74.55
Avg Volume
1,988,974
Gross margin is running at 64.5%, which gives a quick read on operating quality before you open the full model.
Net margin is -42.4%, useful for comparing GH against peers in Health Care.
GH is down 10.9% over the last 30 trading days shown on this page.
Latest operating income is $-121M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$27.28
Rule of 40
9.1%
Dark Pool Short %
69.1%
Latest Close
$90.36
30-Day Move
-10.9%
Market Cap
$12.3B
Shares Outstanding
131,170,000
P/B Ratio
20.69
ROE
-302.1%
ROA
-20.7%
Gross Margin
64.5%
Operating Margin
-45.0%
Net Margin
-42.4%
Debt / Equity
7.18
Current Ratio
4.84
Latest Revenue
$281M
Revenue
$281M
Gross Profit
$182M
Operating Income
$-121M
Net Income
$-128M
Gross Margin
6446.0%
Net Margin
-4239.0%
Current Ratio
4.84
Debt / Equity
7.18
Fair Value
$27.28
Upside / Downside
-69.8%
Signal
Overvalued
Implied Growth
--
EV/Rev
$27.28
Growth Assumption
29.8%
Discount Rate
9.2%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
1.88
Grey
Piotroski
5
Moderate (4-6)
Cash Conversion
0.44x
Rule of 40
9.1%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $450M | $-544M | $-655M | $-387M |
| 2023-12-31 | $564M | $-565M | $-479M | $-345M |
| 2024-12-31 | $739M | $-444M | $-436M | $-275M |
| 2025-12-31 | $982M | $-437M | $-416M | $-233M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$656,756.36
Buys
0
Sells
4
Buy Value
$0
Sell Value
$656,756.36
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-17 | Hidalgo Medina Manuel | M | 232 | $0.00 |
| 2026-04-17 | Hidalgo Medina Manuel | M | 232 | $0.00 |
| 2026-04-16 | Tariq Musa | Sell | 116 | $84.83 |
| 2026-04-15 | Tariq Musa | M | 250 | $0.00 |
| 2026-04-15 | Tariq Musa | M | 250 | $0.00 |
| 2026-04-15 | Saia John G. | M | 7,569 | $0.00 |
| 2026-04-15 | Saia John G. | F | 3,970 | $84.86 |
| 2026-04-15 | Saia John G. | M | 7,569 | $0.00 |
Vanguard Group
Filed 2026-01-29
$1.2B
+2.1%
Invesco
Filed 2026-02-19
$543M
+7.8%
Geode Capital Management
Filed 2026-02-09
$328M
+9.4%
BlackRock
Filed 2024-08-13
$325M
--
Goldman Sachs
Filed 2026-02-10
$268M
+74.4%
FMR LLC (Fidelity)
Filed 2026-02-17
$245M
+190.7%
Two Sigma Advisers
Filed 2026-02-17
$243M
+12.8%
4.29
Consensus
Buy—
—
—
34
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.